Enhanced Performance of Internal Limb Lenthening Prosthesis by Pasma Immersion Ion Implantation

通过 Pasma 浸没离子植入增强肢体内延长假体的性能

• 批准号: 132377
• 金额: $ 8.83万
• 依托单位: SMITH & NEPHEW UK LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132377
• 关键词: Enhanced; Performance; Internal; Limb; Lenthening

The objective of this 1 year feasibility study is to improve the performance of limb lengthening intramedullary prosthesis (LLN) for deformity correction & acquired trauma through plasma immersion ion implantation (PIII) of the internal components. It is hypothesized that PIII treatment will improve lubricity between these mating surfaces reducing the torque required to lengthen the nail & allowing for use in patients with larger limb diameter. PIII will require in-line control of critical process characteristics, e.g. implantation current, dose, choice of dopants, & surface characterisation tools to assess coating composition & coefficient of friction. The vertically integrated collaboration between a global medical device company (S&N), a specialist in PIII treatment (IBS), & an institute specializing in surface characterisation (NPL), are requesting £79k to address processing challenges relating to surface characterisation, process design & scale-up. The platform technology is applicable in other healthcare & industrial sectors given its high level of innovation, & the partners will commercialize the results through the consortium.

这项为期1年的可行性研究的目的是通过等离子体浸泡离子植入（PIII）改善肢体延长髓内假体（LLN）用于畸形矫正和获得性创伤的性能。据推测，PIII治疗将改善这些配合面之间的润滑，减少延长钉所需的扭矩，并允许在肢体直径较大的患者中使用。PIII将需要对关键工艺特性进行在线控制，例如注入电流、剂量、掺杂剂的选择，以及评估涂层成分和摩擦系数的表面表征工具。一家全球医疗器械公司（S&N）、PIII治疗（IBS）专家和一家专门从事表面表征（NPL）的研究所之间的垂直整合合作，要求7.9万英镑用于解决与表面表征、工艺设计和规模扩大有关的处理挑战。该平台技术具有很高的创新水平，适用于其他医疗保健和工业领域，合作伙伴将通过联盟将成果商业化。